X4 Pharmaceuticals names Dr Gary J Bridger as board member
5 November 2018 -

Clinical stage biotechnology company X4 Pharmaceuticals revealed on Monday that Gary J Bridger, PhD has been appointed to its board of directors.

Dr Bridger currently serves as a board member of Aquinox Pharmaceuticals. Previously, he was a co-founder and chief scientific officer of AnorMED Inc, through its acquisition by Genzyme in 2007.

Earlier, Dr Bridger was a board member for Alder Biopharmaceuticals and had also served as executive vice president of Research and Development of Xenon Pharmaceuticals, as well as managing director at Five Corners Capital.

X4 Pharmaceuticals is currently developing novel therapeutics that are designed to improve immune cell trafficking to treat rare diseases and cancer. Its oral small molecule drug candidates antagonise the CXCR4 pathway, which plays a central role in immune surveillance. The company added that its most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumours.